{"ticker": {"uuid": "da05e924-2410-4fdc-ae9c-7a87bb611124", "symbol": "INCY", "name": "Incyte Corporation", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Truist raises Incyte stock price target to $105 on VWD outlook", "summary": "Truist Securities increased its price target for Incyte Corp. (NASDAQ: INCY) shares to $105 from $103, maintaining a Hold rating. This adjustment reflects a one-time $246 million addition to Opzelura net sales in Q2 2026 and incorporates a 5% decrease in Opzelura gross-to-net goi", "url": "https://www.investing.com/news/analyst-ratings/truist-raises-incyte-stock-price-target-to-105-on-vwd-outlook-93CH-4753498", "source_name": "Investing.com", "published_at": "2026-06-22T18:20:08", "published_display": "22 Jun 2026 18:20", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Incyte settles Medicaid rebate litigation with CMS, expects $246 million benefit", "summary": "Incyte Corporation has settled a Medicaid rebate litigation with the Centers for Medicare & Medicaid Services (CMS), expecting a one-time non-cash benefit of approximately $246 million in the second quarter of 2026. The settlement resolves a dispute over the application of Medica", "url": "https://www.investing.com/news/sec-filings/incyte-settles-medicaid-rebate-litigation-with-cms-expects-246-million-benefit-93CH-4752318", "source_name": "Investing.com", "published_at": "2026-06-22T11:37:57", "published_display": "22 Jun 2026 11:37", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Incyte reaches CMS settlement, to record $246M non-cash benefit after Opzelura ruling", "summary": "Incyte announced a settlement with CMS regarding its drug Opzelura, which will not be treated as a line extension of Jakafi under Medicaid rebate rules. This agreement will result in a one-time non-cash benefit of approximately $246 million in Q2 2026 for Incyte, stemming from th", "url": "https://www.tradingview.com/news/tradingview:d76139d28d83b:0-incyte-reaches-cms-settlement-to-record-246m-non-cash-benefit-after-opzelura-ruling/", "source_name": "TradingView", "published_at": "2026-06-22T11:03:03", "published_display": "22 Jun 2026 11:03", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BMO upgrades Incyte stock rating on strategic progress By Investing.com", "summary": "BMO Capital upgraded Incyte Corp. (NASDAQ:INCY) from Underperform to Market Perform, raising its price target to $94 from $75, citing significant strategic progress under new leadership. This upgrade follows a prior downgrade due to concerns about the loss of exclusivity for Jaka", "url": "https://m.in.investing.com/news/stock-market-news/bmo-upgrades-incyte-stock-rating-on-strategic-progress-93CH-5463541?ampMode=1", "source_name": "Investing.com India", "published_at": "2026-06-22T09:38:03", "published_display": "22 Jun 2026 09:38", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Incyte Stock: Is INCY Outperforming the Healthcare Sector?", "summary": "Incyte Corporation (INCY) is outperforming the broader healthcare sector, with its stock rising 6.5% over the past three months compared to the State Street Healthcare Select Sector SPDR ETF\u2019s (XLV) 1.5% increase. Over the past year, INCY surged 43.9% against XLV's 12.1% rally. T", "url": "https://www.barchart.com/story/news/2577260/incyte-stock-is-incy-outperforming-the-healthcare-sector", "source_name": "Barchart.com", "published_at": "2026-06-22T09:37:58", "published_display": "22 Jun 2026 09:37", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Incyte Stock - Sunday background on the biotech\u2019s position in a crowded field", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxPd21xSmtPZ3pRbXhwb0JjMDJRZERFcDl5dWhmOXhEeEFiVUF2ZTNqN1lMbVNRWEpOb0txd3o0eVFoNFFHSHJKanVUMXRmYWNfcmlRR3luUFVQT3JRUDJnVzJ4UF83RFMxNUpYY2RESjZsV2p6U0Z1U3cwZjA3ZExrazdZSWk1Z2FKR2w0SnZxX0N6Vnc1NkNpN1dtRHU4WmRaaURTUmxjR3dna0JzZXFQZ2hfWWptYURjWlJKVElDLWxKZlJSSW1r?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-06-21T19:37:28+00:00", "published_display": "21 Jun 2026 19:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Incyte Stock - Stifel lifts price target after bile duct disease data", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOT0tBTVNmQ25haW1tYm1VQlJUMTFUX3Ztd182UFdpb29Md3ltUUpIRkd6dEVuZ0FuMnRnVklmQ0l3WG9vaEQtOEtMUms4OWFQS0dUVlZ6b1dMYTNDUEJoTTFCNFdDTlhpOFpKY2pLaUxEV0JoSXpCakpqbEtOYXBhQkZXdWNMeVFvOEFSZ2M3RkZKWmlvc3JPSk5fQkI4akpuR0VSYlBxUFVrYlVHcE1ZbHJZQTVQejhQOXJYM0twZC15TFlX?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-06-19T19:57:15+00:00", "published_display": "19 Jun 2026 19:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Incyte secures Japanese approval for lymphoma drug Minjuvi", "summary": "Incyte has received regulatory approval in Japan for its lymphoma treatment combination Minjuvi, which achieved response rates up to 71.4% in clinical trials. This approval provides a new treatment option for patients with relapsed or refractory large B-cell lymphoma, especially ", "url": "https://grafa.com/en/news/united-states/incyte-receives-japan-approval-for-minjuvi", "source_name": "grafa.com", "published_at": "2026-06-19T10:19:58", "published_display": "19 Jun 2026 10:19", "sentiment": "positive", "sentiment_pct": 75, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Incyte Corp (INCY) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Incyte Corp (INCY), highlighting its current price momentum score, support and resistance levels, and various technical indicators. It details the readings for MACD, RSI, KDJ, and others, along with moving averages, to suggest an over", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-incy/technical", "source_name": "TradingKey", "published_at": "2026-06-19T09:37:50", "published_display": "19 Jun 2026 09:37", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Japan clears Incyte\u2019s Minjuvi for relapsed DLBCL patients", "summary": "Incyte Biosciences Japan G.K. announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This approval is b", "url": "https://www.stocktitan.net/news/INCY/incyte-japan-announces-approval-of-minjuvi-tafasitamab-in-ypimwbywb65n.html", "source_name": "Stock Titan", "published_at": "2026-06-19T06:03:20", "published_display": "19 Jun 2026 06:03", "sentiment": "positive", "sentiment_pct": 70, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INCY News | INCYTE CORP (NASDAQ:INCY)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiW0FVX3lxTE5ucXFWeWVvMEh6ZGhqT0pYQUZiZjNnMWV5QUtrMHhsOFpxNVQzMmNpczZHQ2Z2RTNzVXVVbkFPUXl0czJYX1NkOS1MQ2FpVmRUdzJ1OXktLWZqaVk?oc=5", "source_name": "ChartMill", "published_at": "2026-06-18T19:49:00+00:00", "published_display": "18 Jun 2026 19:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Incyte Stock - Thursday technicals and trading range in focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQcFJFb1BzNGwyTm9SQ1U4Z29mVi00dGdLX1BYRlpaLTY3MklvQngtckE0TEo3UV9iaFdVb29JbG1wWE96RkRPU3FHQWNzU1luaDV2OC00azlZeG40Wk9XQUliZWh5X3k2TXZGN09ObndhY1ExQ2ZQUlVqUnI5WXoxVVhOSktPbjZwR0ZESjM5WVN1R0k2eDFVdTl1NnpVcUFkSHB0QWthQUJGZ2RfM043S0p5YmJVOVI4Zmc?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-06-18T13:04:25+00:00", "published_display": "18 Jun 2026 13:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Incyte (INCY) Stock Could Be 8.1% Undervalued After FDA Priority Review And Trial Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-17T10:57:27+00:00", "published_display": "17 Jun 2026 10:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)", "summary": "Mirum Pharmaceuticals (MIRM) and Incyte Corporation (INCY) announced positive phase II results from their PROGRESS study for zilurgisertib, an investigational oral ALK2 inhibitor for fibrodysplasia ossificans progressiva (FOP).", "url": "https://www.tradingview.com/news/zacks:8fa130e27094b:0-mirm-incy-report-positive-rare-disease-data-as-fda-begins-nda-review-revised/", "source_name": "TradingView", "published_at": "2026-06-17T10:37:59", "published_display": "17 Jun 2026 10:37", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Incyte Corp (INCY) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Incyte Corp (INCY), highlighting its current earnings forecast score of 7.14 within the Pharmaceuticals industry and an average price target of $101.00 based on 28 analysts. The majority of analysts recommend a \"Buy\" for INCY, with e", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-incy/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T06:38:17", "published_display": "17 Jun 2026 06:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Incyte Corp (INCY) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Incyte Corp (INCY) has a robust financial health score of 9.25, ranking 7th out of 157 in the Pharmaceuticals industry. The company reported a significant year-over-year revenue increase of 20.87% to $1.27 billion, with net profit soaring by 91.73%. These figures indicate strong ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-incy/financial-health", "source_name": "TradingKey", "published_at": "2026-06-17T06:08:11", "published_display": "17 Jun 2026 06:08", "sentiment": "positive", "sentiment_pct": 77, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Incyte Corp (INCY) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "Incyte Corp (INCY) has a risk assessment score of 8.15, ranking 27 out of 157 in the Pharmaceuticals industry. The company's beta of 0.79 indicates it tends to underperform in up markets but has smaller declines in down markets. The U.S. Dollar Index's neutral state has a neutral", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-incy/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-17T06:08:06", "published_display": "17 Jun 2026 06:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Incyte Stock (US45337C1027): Clinical data and earnings outlook keep Nasdaq biotech in focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxQVHIyZGFHcWNSaFhybjZfb2J1VWp6WWlWSTVnT3NQZW1ZcFVIdEdJZDhTRFpHVENmamp5ZThNLVVxQ1JJdTBKbXBvYmlLbEgzUjB1RkdKOVJUaGpIUUNqcW5oOUFMREZPcjJPSDBYRnV3N2xyTTZtZFdBOEw3M0JBMUFNODhiMEZuMjFGaXNnT1BuX2ltbVk1dWNacTVQT2JJVEVsbXRCTkVrN2UxX0czT2RyRzQ0djVrUDRGU3d2RXBOdw?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-06-16T14:33:44+00:00", "published_display": "16 Jun 2026 14:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Conflicted on These Healthcare Names: Incyte (INCY), Intellia Therapeutics (NTLA) and Halozyme (HALO)", "summary": "Analysts have issued conflicting ratings for several healthcare stocks. Incyte (INCY) received a Hold rating from Wells Fargo, with a Moderate Buy consensus. Intellia Therapeutics (NTLA) was rated Buy by TD Cowen, holding a Moderate Buy consensus. Halozyme (HALO) also received a ", "url": "https://www.theglobeandmail.com/investing/markets/stocks/NTLA-Q/pressreleases/2489035/analysts-conflicted-on-these-healthcare-names-incyte-incy-intellia-therapeutics-ntla-and-halozyme-halo/", "source_name": "The Globe and Mail", "published_at": "2026-06-16T11:07:52", "published_display": "16 Jun 2026 11:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Offer Insights on Healthcare Companies: Incyte (INCY), Pfizer (PFE) and MBX Biosciences, Inc. (MBX)", "summary": "Barclays analysts have provided insights on several healthcare companies. Etzer Darout maintained a Buy rating for Incyte (INCY) with a $117.00 price target, while Emily Field issued a Sell rating for Pfizer (PFE) with a $25.00 price target. Eliana Merle maintained a Buy rating o", "url": "https://www.theglobeandmail.com/investing/markets/stocks/PFE/pressreleases/2486608/analysts-offer-insights-on-healthcare-companies-incyte-incy-pfizer-pfe-and-mbx-biosciences-inc-mbx/", "source_name": "The Globe and Mail", "published_at": "2026-06-16T08:40:35", "published_display": "16 Jun 2026 08:40", "sentiment": "positive", "sentiment_pct": 63, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BMO reiterates Incyte stock Underperform on ET/MF trial data", "summary": "BMO Capital reiterated an Underperform rating on Incyte Corp. with a $75.00 price target following updates on its mCALR antibody candidate, '989. The firm noted decreased efficacy in larger patient groups for essential thrombocythemia and mild regression in myelofibrosis monother", "url": "https://www.investing.com/news/analyst-ratings/bmo-reiterates-incyte-stock-underperform-on-etmf-trial-data-93CH-4742640", "source_name": "Investing.com", "published_at": "2026-06-16T04:37:57", "published_display": "16 Jun 2026 04:37", "sentiment": "negative", "sentiment_pct": 36, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Behavioral Patterns of INCY and Institutional Flows", "summary": "The article analyzes Incyte Corporation (INCY) with a strong overweight bias based on AI-generated signals across all time horizons. It identifies a mid-channel oscillation pattern and presents an exceptional short setup with a 34.6:1 risk-reward ratio. The analysis further detai", "url": "https://news.stocktradersdaily.com/news_release/17/Behavioral_Patterns_of_INCY_and_Institutional_Flows_061626025001_1781592601.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-16T02:50:00", "published_display": "16 Jun 2026 02:50", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Incyte slides as investors digest updated INCA033989 (mutCALR) data and a cautious analyst take", "summary": "Incyte (INCY) shares dropped 6.0% after investors reviewed updated clinical trial data for INCA033989, a mutant CALR-targeted antibody. Despite the company highlighting rapid and durable responses in essential thrombocythemia (ET) and myelofibrosis (MF), the stock reacted to perc", "url": "https://www.quiverquant.com/news/Incyte+slides+as+investors+digest+updated+INCA033989+%28mutCALR%29+data+and+a+cautious+analyst+take", "source_name": "Quiver Quantitative", "published_at": "2026-06-15T21:20:55", "published_display": "15 Jun 2026 21:20", "sentiment": "negative", "sentiment_pct": 38, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Incyte Corp. stock underperforms Monday when compared to competitors", "summary": "Incyte Corp. (INCY) shares decreased by 6.04% to $101.98 on Monday, despite a generally positive trading session where the S&P 500 Index and Dow Jones Industrial Average both saw gains. This fall ended a four-day winning streak for the company's stock.", "url": "https://www.marketwatch.com/data-news/incyte-corp-stock-underperforms-monday-when-compared-to-competitors-30e24eda-2ba4092076ab", "source_name": "MarketWatch", "published_at": "2026-06-15T20:30:00", "published_display": "15 Jun 2026 20:30", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Incyte Is Dropping 5.6%: HC Wainwright & Co. Maintains Buy", "summary": "Incyte Corporation's shares plunged 5.6% despite HC Wainwright & Co. maintaining a Buy rating and increasing its price target from $135 to $140. The market's reaction, with heavy trading volume, suggests investors are focusing on broader sector weakness, potential FDA regulatory ", "url": "https://news.alphastreet.com/why-incyte-is-dropping-5-6-hc-wainwright-co-maintains-buy/", "source_name": "AlphaStreet", "published_at": "2026-06-15T19:44:53", "published_display": "15 Jun 2026 19:44", "sentiment": "negative", "sentiment_pct": 37, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Incyte Corporation (INCY) Stock Analysis: A Biotech Innovator with a Robust Revenue Growth and Promising Pipeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8wFBVV95cUxNdG0yZ0pxNS04T3F1bzlfdldIX29oUzlFWHFpNm9PWVlmalVSRjBNWS1YTHNWZlNQVlRCQ1pHWjlyS3VVbHlQclZQSm9wc1pqTTdfY09NZ0N5c0tZSmZILUY1MnR3Slphel83aGFpRXAxS0R0Wk9LVmRROVdlZGxJdXEtdG9pWUZTQXNHMjQ0clVtS1doM1p0QVBFRHRrN2xXZEF5aUhQUEFjUkJGUVJlVTZzMVRqcUZvTDQwMkptbEFxTUw3LU4wVk5maE9lc0M5X2RZdzJBdzlLVzhCRENnM0pBNkNVNTl5dl9DSDJLdGhvYkk?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-06-15T09:13:37+00:00", "published_display": "15 Jun 2026 09:13", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Incyte antibody speeds platelet normalization in MF and ET trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxONTJaWldyWHNmbTg3c2lwcnItdk9mLVFLcUwyTFB5MC1LWGxJZFZfNXdEaFpGQ1FTdDg3allzODRyaENNZXdaTE50S3RCQWJXYzA1SE8xNVMxejhVMHJLU2RvWWo4cEQ5eHg0Z2dNRjAzZ3BLaW5mdjNzSmgyWUFJeGhiV1V2bjNMWENBRUpaTnZFOGEweS1LMzlGUzVXN2Rzd0ZsY0JYeHNCWE9sR0lkTzg4ZlJVN3VLOV9J?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-13T15:15:00+00:00", "published_display": "13 Jun 2026 15:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Incyte Stock (US45337C1027): Ownership shifts and pipeline focus keep shares in view", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxPQ0EtclJTazlVTzA2NEJ2RzV6LTRicTR1OEtCMlBvaUlNbVp4bEtPN1pGS185d2s1TlB2bk1HMGtKX0RBYW1CR0w2QmM5cU0weEdJeDg4YWV3S3JqbWVuV2hxQ2ZSLVRESlZPeDBoT0QxUWFIWEhBTWE4Z185ci1DV3JrS1otVTBKeXVtT2lUbjFqbGx1cVNBZ3F2LXY1c19lVVFCUmVFay1WVGtqTE1VbExvR1d5QjZkbDJXRHo1ODZLd3c?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-06-13T14:50:29+00:00", "published_display": "13 Jun 2026 14:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Incyte Stock (US45337C1027): Quarterly trends and sector context for US investors", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxOckxjX2hsMWNwc0haMFFTUDYzSjcyVHFVNHp1NFg4QXZWYW82Y3p4cGZpdERicTRUVVowemFSSFBZa2pQa0gtTWUyVTlmLWpLcmV4SXBkTlB3QzEzdzVzdkZkcml5aXkyT0dXblRLYUh2VkNlalpEbGFHU2Nfb2xDY0t4UEMtX214TUFvazBZamlJYURLc1g3QXhXOEdVRnVSM1hKTU5FRE0zbVJTTGhBNk9QUFZaRFJGdVN4SDFYc2t0MGtIdWc?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-06-12T08:05:21+00:00", "published_display": "12 Jun 2026 08:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Incyte a Better Buy Than Regeneron Pharmaceuticals?", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxQeEJUcW9pQ2IybVJvanh6TFNjeFFQbktWeUYxM2RiYWxtRzJ6V01tRHh5VllXVjcxVzhLUWpRYU9jMThUUjJrX09JdGdDN2ExTHNUUDRLTDdwenQzRVd4YlVwQzlqNmlId1BNbThDc0xNUmNGMlNCeU1CN194cW1mQlBYVlA3RnNJS2VPTy1TVnI2bnlhQjgtSHRGeHhFR2lxT2lzbEwwX0swM1hpVTY3Q2kyX04?oc=5", "source_name": "Trefis", "published_at": "2026-06-11T06:45:47+00:00", "published_display": "11 Jun 2026 06:45", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Incyte (INCY) Stock Is Up Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxQQ05OclRmVmRWM3NORGJHMzZ3RDNWNDI2cnM2WXZUSnJTdzZoRl92WjY0cDU5SFJjQjgtTWw4b01UZnNBWTF5alRobEJjVHd2MThkS0hBcWpZbTdfa2F1SGRMWlI0emVVUVRlMUNEaFM4cWpRVEdaYVBrUkVyUC1oam1RQlFac3F5QmZ4UUZ2OTkyVGhxS2EwRVFMMA?oc=5", "source_name": "StockStory", "published_at": "2026-06-10T16:15:00+00:00", "published_display": "10 Jun 2026 16:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Incyte to Buy Vega Therapeutics in Hematology Deal Worth Up to $2B", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQUDduNFJOWlY1ZjNXa3p0SDIxT3QxWDJvMlE1TGxwZTNlUWlNamxkUnI5THNIeEI3dEcwSmctMEladzZfX0pLMDFBWWQ2d0FxaTZ6a28wUWE1VmZ2d0kzbDl4dWJGTHZCSjhIeHhQckdGbC14SnhxUm9CazlWOUtMQWlBRVlodzE3VVY3RjNmTGE4SER5bU9EX2w5X3ZrbHhWVXNpRjljeE5pVXFETXNNMENIU3R2eDRXREo4ZW5B?oc=5", "source_name": "TradingView", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Incyte Corp (NASDAQ:INCY) Screens as a Deep Value Opportunity with Strong Profitability", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxOWFVlcU50TUMxa1owUkdndWwyNDY2SW80V3lLc3c4bDRQN3lrQUw1TnFQNERTdzh0RXZkUmw1RzRESUpDTjJCZHZxVks1T0l3Z1lqWUdfcGM1X2c2Tk80d0t2blVXX3k4eDd5MW5sT2dJbUkzV1NjY1dJdS1PRjhrQ0FNTU9UMHV3OV9pS2p6R3VnNHdHeEw0TGNZN2xkTFkzcXNudVBMUnFyeTVCZE1QdTY2ay1KazE5UDRyWURKMkp0d2w1bWw4Vk44R2xMQXMzR3c?oc=5", "source_name": "ChartMill", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Incyte shares rise 6.2% amid renewed optimism around late-stage pipeline and recent partnership update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxOenVCZlpfeW9CNXJCUmhoeUM1YWRHaHlZdnNadUhBTUpNTl9ZUmlXdHo5VHhEWWhpeHdPTFV2UTl5TmJfalp6b1dvdGMzV3hNQXI5Wm1zQmlaWVNvdkJZY2ZUMmlUTXdjZWJtRkJCTjBtQTBkejA0U1ZBN2FEZElDWlVqcjNwYmh2UXloUjFPaVdNWTRZVE1WdTVlT3NnYkxjcWtqZy1ZR2U1Uk1SdmZwVC1XbHU4UXp0aEQ4c0FRdHNGYUpJNUdUS2hvWWhnT3pRNkVv?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Incyte Corporation (INCY) Stock Analysis: Exploring a Strong 11.6% Potential Upside for Investors", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxOMV9sNkNFNDBoeGZzREV1eTlKZWVGN04xV1JTMThMN2cyYmp1SDlHS0dUYkRxVjFVRHFiYzNmdExfNlhKT0VSRnRWR3dubWtEb3M0THpudHNjM3Q4TG5TbUVWcXhnSGd1WGNLVWU1WXJxeWY0Y18tbksxZnhvelFTOXktU0VJX1NJREE3a21KNW9MWVpjUHh5b0RlbXRXZ1k3VFZzRm1lVktydTc3YjU3OFJqbmotdHNidk5mT2lmTHdBSUxCZ3RYOVY5c3lqTm1sbVZidmIwRzJDTkkt?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Impressive Earnings May Not Tell The Whole Story For Incyte (NASDAQ:INCY)", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-10T07:00:00+00:00", "published_display": "10 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jakafi XR Approval Tests Incyte Valuation As Growth Outlook Softens", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxPSVRUb290T3JFbHUwTVdjYWFyaUJaazU2d1BOMjRGQjgxclp3ajJwQVBXVFRLWmlYWDJ5eDZBZXJxUDBzOUczNmNYY2ZLdkRsMV9TY1pKRGxhbi1zREEtVFkxMzZndDFSRFZCNmNLbjF6T3pqNFdyQVE3eng4ZEdkX3J3YURKNlF3dTQ1cmRqLUdrQVNJZmliWlhjQWZLUzRxMElVR0l3bFRPZjdNRVBFdWI3M3NmVFh1MnRPVF9mWnhYaU1VMWgwTFNOMGpPTkRCVUU1ZVF30gHbAUFVX3lxTE1JTmpVOU1Ua3lkR21jaTl3ZzdRZnFlbFpUNDBJZ0VrUnV2VWEwcVhUTnpxOUtWcXU1TWQzdnV6TzNXNUlxcU84M1FmX2p2ZGVadzE4eXZaRXhBcWI1dERfdFZOd3NRdGJZNXgta2pGdmRYTmh6U2tJVWZlenZ0bmhZZndOdUtscXE4M1lmQ1daMG4yZnY4aks1OFZtc1phWnVSeUZjM2FDcHZFal9DdWlET0lwS2xETVRaQ0ZMYmtIbkJWSHNVd2g2dlNpeXNUX3JrSFlHLUt4cU8wTQ?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Consider Incyte (INCY) After A 55% One Year Rally?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxPYmNRalQzX1p0SHVudWdaWE5ta2NGX3piRFh5QXhTOTJlMlVrZmhZRVJYWGkybG14SE5DcktHMHdKMlhwOHVlV2lXRzRrX01zV0FCeno0dm5OM2FWM05qM1lYN2FhblJHQmNqNi1SLWduSENnMzdrQXZlZENtZ2tiT25MaFlUQ1hRbE0zY2xEMEl2Y3hwR2NhR2pacFRtaVZIWFB6cGNaYml0Qm9sQjRnQm44YU5pMUFBM0V0MmRpWEZHR1FsU0xpbFExX3dsc09jRGpuRWRpWdIB3AFBVV95cUxNN0R3dGw3akp0Wi1zdnJPWFE4bC1ETDdNYU1MaG10V1VCRm1TT292MHZVM09GSHhJNXJBQVRmMFI4UU1yLWZvaUc1U2M1Q1QxNWdMZkhqNHpSYkxCN2NYMndRdUtXZHNHVXJ0SWZRbmFWck5ucjVrSXV3OE01QThhM0ktbFZjbHVjUm1YWmFIbW1Ra2FGUlFJM3VEQUpHSWdfcTlYMzQxVm9IRUxhcVVQM1F0aDR1Nzl1MVM5SnpTZWM1ZWlSa2hwSGhJdzVPSVpoMThYYW8ycldOVExS?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-02T07:00:00+00:00", "published_display": "02 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "One pill a day: FDA approves Incyte's Jakafi XR for 3 conditions", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNelJqN3I0SmRrRmFFdi1EazhfbmlPSGIzVnh6U1lXcmhZZmNyMTVPOFgxb1ZEMXhPRVJubmZudDg1NFlyVVZ5a1FkMkloUHpiaVFzaVpFZW5HZmhHUUs0bk9sRTB3ckNRYUNjVjZvRDlZMmIwaE5ZdEZoY3Z4VGlGWi0tM2JtWnNTbUE1c2xweC02ZS1XQm5LYWd1SXZCWEliMEdEd012MTU1NmpsMGgzTVd4dWh3bm0wTXdXRw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Incyte (INCY) Margin Reset To 26.7% Tests Bullish Profit Durability Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Incyte (NASDAQ:INCY) Beats Q1 Estimates and Unveils Robust Pipeline Catalysts", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOOW51ZjBlYUxHSjBUR3NsT2Y2MENXSXEtYkViTEwwMGd2Tm0wTTJpOW9vTTAyM2gxWVgtOWY1TjlvZFZZOXEwUklhY1lCZ3pBdGlHTTB3WHRaVVEzX1pMYjZnSUo3ekFnSlg5WHh2TW8wcU91ZTRMdXc1aHZtVHpOTmd3X2FESndBVnczcXM1QlNNc0dRUUZaajVIWFlGbS1pSW1nVnJXM095OVQ2TUZvd3BnZmpscm5tRVJaT0ZoU1JYbWpy?oc=5", "source_name": "ChartMill", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Incyte Gears Up to Report Q1 Earnings: What Can Investors Expect?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQR2h2RzNYQjhHeVU0Ul8tNTFsUllVRFRIMXUtNEthTU5fNF8xOXpEVVQ1LUVzY1BqYW9pMEFPaFhpYkUxWmcyNHJBZ0hub1ZDY2JmcVlQNVVFcjZka2pDOTY5ZUl5SGJGUnhEUjE0QzJCVnpWZHEwTUlwS25QRTRYWEtscHBXYXN3RkNzYnVXc013aDUxWVYya2NaNk9ZZlp4VHJhWEZUb2lVUXJCMW9tNVYyVjZyVGRrZ2tF?oc=5", "source_name": "TradingView", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Incyte (INCY) Stock Analysis | Incyte Corp Posts 8.5% EPS Miss Vs Consensus Views - Banking Earnings Report", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxOVFA1YUVTb0xLQWV6N0t4NTMzTC1qa2NzZllURDVwOFdQaXlTRFRTNlRGYXpNVlh6dVFhUXlJRW9wRFM0T1A5R3h2ZElzN2U4emJLSFJxNWtaSXlKRkpmQXZCWE9lQ2JyRk13ZmNwN25kMndKUHlRcDdvZUVmUm84X0dPYkxqbFBacXUyRFN6Q3BfcDVqZGt2Z2ZVWEg3UF9tOG5wcjJVdEpTbHd6aDBfd1Nn?oc=5", "source_name": "lwvtexas.org", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INCY Stock Analysis: Incyte Corp biotech stock rises 1.73 pct near 96 dollar mark", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxQcFgwSTl6UVBGY0hGQlhjYlZ6TjNuUGdBaVgyNDBkNV9BY0l2WkRPV2F0ODRUSTZXcWpQZTRGZUNDa0lGZTZKbGJaaEtfUDM3QkhFODNIc0MzekV5WXRxN1h2RDU1ejJDOEVIMlM2OHRXRlV5Ti1WR2xFRVQwNFB6LUhkdnNqT3BGdmlHTEdfeUEyS2RzVFZJb0t5dzR6RjM3c25MaTF5UldMXzJ5NTRTenJSSFJRbGlhVVBISG5VYzNhZkJIUzBkdkhR?oc=5", "source_name": "lwvtexas.org", "published_at": "2026-04-03T07:00:00+00:00", "published_display": "03 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNZXlTZHFHZVNxMktqZ0hVNURmdE1hUFpZZnlfdEVhMnVla2EyTWN6b2YwNkVhNllxUy1Bczl2a0ZUNk04Q3oyTEZSajdpMnFDVXJfRTlfLUdHQ05uS3FQZkhNWkJ0MDFENDJvRXR0ZGV1RDlYVmdWem96V29NeTg4YWRZWGNoMzM1emRoSExJbXdwZnJIWHpsYjVnT0FQVHZtUW5iVg?oc=5", "source_name": "Market source", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Incyte Shares Drop 8% Post-Earnings: Analysts Target $104 Amid 2026 Guidance Concerns", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPX2ota2xxdzhJU0JNOHhDcmtsZHZvS1k1NGZ3Y2FQajJDTUp1TEF6ckxPVXVmaEU5R0ptS1RJNnRFcTdGVGRLS3VJWjk4VllUaU9fQVRTU3Q0VWlMX1djVnBXX0hFY3FPMzNHanZTNXhpeVhIZ3BLR1ZNczl0dmVna1JHWTRYdTFqYjFmWjFiV0ZMOHRnY2M0bzJYaVQ4QVA3bU9IUkF2RkRLdlF5?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-11T08:00:00+00:00", "published_display": "11 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Incyte (INCY) Stock Is Nosediving", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxOZGpma0o0NWdYU0trcVNGN1lPWEVscThjSHloTERUSE5INnlpQXpYNktTZktaTUtVRXdZX25qZmFBTlZTcDYta3QxSUV0Y3ZfTzdEQkRKYkZ2cGJkU3Y1ZU5CX1M1Mm9DVzk5Z2FFOHJCZWVHY2N4Q1dhOVJlS3VKS1JxMnU?oc=5", "source_name": "Market source", "published_at": "2026-02-10T08:00:00+00:00", "published_display": "10 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INCY Stock Price and Chart \u2014 NASDAQ:INCY", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE52MEF3WHRDbDVpZHhrc3B4ejdpZWFNQXR0MElhRVFBdHNsRzZnVHB1WEtzaTdnbUp0S3N2UC1DZlRMRHZubHh5dUhVcFdwUm0zUFRNN1JNOTMzdy1L?oc=5", "source_name": "TradingView", "published_at": "2026-01-26T08:00:00+00:00", "published_display": "26 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Incyte (INCY) Stock Is Up, What You Need To Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNcEVObVhOODFvSlBHWS1DX0tlck1fOEstcmEwOUhIbnpLZ1puSlk0RWoxckdRbHY3Y0hoOUFqSHdHRFBqN1FqWFNYMllsdDJuRllVRkV6WWxaWGdoSEk0WVNiV0dDNHBLVXdYNW1maV9Wd0NyV21DOFVlb1ZNV1U5N19nMFpDTGJRMmhMZ1FyY25ETDRROGpvdno1SzdCSm1TaUljYTlrVDgteGZBVlE?oc=5", "source_name": "StockStory", "published_at": "2026-01-07T08:00:00+00:00", "published_display": "07 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Incyte and Winnie Harlow Join Forces to Share Her Personal Vitiligo Story and Spark Conversation and Understanding", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxNWGZFR2NTV2dLby04Q1pQcVNMd3owSDVIYndvOXl6VHlMUHpfTEJqUzZtUms3VHNBNmFIN3AwOUJxeXJwcVY2QWYxZGdlM2xWTENnQjVkZ1BLcHNJTm0xZjVXM2Y2VHpSb3ljcGdRRXNKcWFuWmhJdzdMMEdhVGpnZU5ZdkFnY2VKWkpLY1pkWk5qX0cybHQ3U2o5ZzhSMVZtb2NYMlE1bGdjNmNneVFjaDNlMFpyXzdaUGFPNlRQQ2RFZHlxaEVrVHpPclltNmRJNXdQWW5YSjk?oc=5", "source_name": "Investing News Network", "published_at": "2025-12-02T08:00:00+00:00", "published_display": "02 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Results: Incyte Corporation Beat Earnings Expectations And Analysts Now Have New Forecasts", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-10-31T07:00:00+00:00", "published_display": "31 Oct 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Incyte Corporation's (NASDAQ:INCY) Price Is Right But Growth Is Lacking After Shares Rocket 26%", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-08-14T07:00:00+00:00", "published_display": "14 Aug 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Truist raises Incyte stock price target to $105 on VWD outlook", "summary": "Truist Securities increased its price target for Incyte Corp. (NASDAQ: INCY) shares to $105 from $103, maintaining a Hold rating. This adjustment reflects a one-time $246 million addition to Opzelura net sales in Q2 2026 and incorporates a 5% decrease in Opzelura gross-to-net goi", "url": "https://www.investing.com/news/analyst-ratings/truist-raises-incyte-stock-price-target-to-105-on-vwd-outlook-93CH-4753498", "source_name": "Investing.com", "published_at": "2026-06-22T18:20:08", "published_display": "22 Jun 2026 18:20", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Incyte settles Medicaid rebate litigation with CMS, expects $246 million benefit", "summary": "Incyte Corporation has settled a Medicaid rebate litigation with the Centers for Medicare & Medicaid Services (CMS), expecting a one-time non-cash benefit of approximately $246 million in the second quarter of 2026. The settlement resolves a dispute over the application of Medica", "url": "https://www.investing.com/news/sec-filings/incyte-settles-medicaid-rebate-litigation-with-cms-expects-246-million-benefit-93CH-4752318", "source_name": "Investing.com", "published_at": "2026-06-22T11:37:57", "published_display": "22 Jun 2026 11:37", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Incyte reaches CMS settlement, to record $246M non-cash benefit after Opzelura ruling", "summary": "Incyte announced a settlement with CMS regarding its drug Opzelura, which will not be treated as a line extension of Jakafi under Medicaid rebate rules. This agreement will result in a one-time non-cash benefit of approximately $246 million in Q2 2026 for Incyte, stemming from th", "url": "https://www.tradingview.com/news/tradingview:d76139d28d83b:0-incyte-reaches-cms-settlement-to-record-246m-non-cash-benefit-after-opzelura-ruling/", "source_name": "TradingView", "published_at": "2026-06-22T11:03:03", "published_display": "22 Jun 2026 11:03", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BMO upgrades Incyte stock rating on strategic progress By Investing.com", "summary": "BMO Capital upgraded Incyte Corp. (NASDAQ:INCY) from Underperform to Market Perform, raising its price target to $94 from $75, citing significant strategic progress under new leadership. This upgrade follows a prior downgrade due to concerns about the loss of exclusivity for Jaka", "url": "https://m.in.investing.com/news/stock-market-news/bmo-upgrades-incyte-stock-rating-on-strategic-progress-93CH-5463541?ampMode=1", "source_name": "Investing.com India", "published_at": "2026-06-22T09:38:03", "published_display": "22 Jun 2026 09:38", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Incyte Stock: Is INCY Outperforming the Healthcare Sector?", "summary": "Incyte Corporation (INCY) is outperforming the broader healthcare sector, with its stock rising 6.5% over the past three months compared to the State Street Healthcare Select Sector SPDR ETF\u2019s (XLV) 1.5% increase. Over the past year, INCY surged 43.9% against XLV's 12.1% rally. T", "url": "https://www.barchart.com/story/news/2577260/incyte-stock-is-incy-outperforming-the-healthcare-sector", "source_name": "Barchart.com", "published_at": "2026-06-22T09:37:58", "published_display": "22 Jun 2026 09:37", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Incyte Stock - Sunday background on the biotech\u2019s position in a crowded field", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxPd21xSmtPZ3pRbXhwb0JjMDJRZERFcDl5dWhmOXhEeEFiVUF2ZTNqN1lMbVNRWEpOb0txd3o0eVFoNFFHSHJKanVUMXRmYWNfcmlRR3luUFVQT3JRUDJnVzJ4UF83RFMxNUpYY2RESjZsV2p6U0Z1U3cwZjA3ZExrazdZSWk1Z2FKR2w0SnZxX0N6Vnc1NkNpN1dtRHU4WmRaaURTUmxjR3dna0JzZXFQZ2hfWWptYURjWlJKVElDLWxKZlJSSW1r?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-06-21T19:37:28+00:00", "published_display": "21 Jun 2026 19:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Incyte Stock - Stifel lifts price target after bile duct disease data", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOT0tBTVNmQ25haW1tYm1VQlJUMTFUX3Ztd182UFdpb29Md3ltUUpIRkd6dEVuZ0FuMnRnVklmQ0l3WG9vaEQtOEtMUms4OWFQS0dUVlZ6b1dMYTNDUEJoTTFCNFdDTlhpOFpKY2pLaUxEV0JoSXpCakpqbEtOYXBhQkZXdWNMeVFvOEFSZ2M3RkZKWmlvc3JPSk5fQkI4akpuR0VSYlBxUFVrYlVHcE1ZbHJZQTVQejhQOXJYM0twZC15TFlX?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-06-19T19:57:15+00:00", "published_display": "19 Jun 2026 19:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Incyte secures Japanese approval for lymphoma drug Minjuvi", "summary": "Incyte has received regulatory approval in Japan for its lymphoma treatment combination Minjuvi, which achieved response rates up to 71.4% in clinical trials. This approval provides a new treatment option for patients with relapsed or refractory large B-cell lymphoma, especially ", "url": "https://grafa.com/en/news/united-states/incyte-receives-japan-approval-for-minjuvi", "source_name": "grafa.com", "published_at": "2026-06-19T10:19:58", "published_display": "19 Jun 2026 10:19", "sentiment": "positive", "sentiment_pct": 75, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Incyte Corp (INCY) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Incyte Corp (INCY), highlighting its current price momentum score, support and resistance levels, and various technical indicators. It details the readings for MACD, RSI, KDJ, and others, along with moving averages, to suggest an over", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-incy/technical", "source_name": "TradingKey", "published_at": "2026-06-19T09:37:50", "published_display": "19 Jun 2026 09:37", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Japan clears Incyte\u2019s Minjuvi for relapsed DLBCL patients", "summary": "Incyte Biosciences Japan G.K. announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This approval is b", "url": "https://www.stocktitan.net/news/INCY/incyte-japan-announces-approval-of-minjuvi-tafasitamab-in-ypimwbywb65n.html", "source_name": "Stock Titan", "published_at": "2026-06-19T06:03:20", "published_display": "19 Jun 2026 06:03", "sentiment": "positive", "sentiment_pct": 70, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INCY News | INCYTE CORP (NASDAQ:INCY)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiW0FVX3lxTE5ucXFWeWVvMEh6ZGhqT0pYQUZiZjNnMWV5QUtrMHhsOFpxNVQzMmNpczZHQ2Z2RTNzVXVVbkFPUXl0czJYX1NkOS1MQ2FpVmRUdzJ1OXktLWZqaVk?oc=5", "source_name": "ChartMill", "published_at": "2026-06-18T19:49:00+00:00", "published_display": "18 Jun 2026 19:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Incyte Stock - Thursday technicals and trading range in focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQcFJFb1BzNGwyTm9SQ1U4Z29mVi00dGdLX1BYRlpaLTY3MklvQngtckE0TEo3UV9iaFdVb29JbG1wWE96RkRPU3FHQWNzU1luaDV2OC00azlZeG40Wk9XQUliZWh5X3k2TXZGN09ObndhY1ExQ2ZQUlVqUnI5WXoxVVhOSktPbjZwR0ZESjM5WVN1R0k2eDFVdTl1NnpVcUFkSHB0QWthQUJGZ2RfM043S0p5YmJVOVI4Zmc?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-06-18T13:04:25+00:00", "published_display": "18 Jun 2026 13:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Incyte (INCY) Stock Could Be 8.1% Undervalued After FDA Priority Review And Trial Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-17T10:57:27+00:00", "published_display": "17 Jun 2026 10:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)", "summary": "Mirum Pharmaceuticals (MIRM) and Incyte Corporation (INCY) announced positive phase II results from their PROGRESS study for zilurgisertib, an investigational oral ALK2 inhibitor for fibrodysplasia ossificans progressiva (FOP).", "url": "https://www.tradingview.com/news/zacks:8fa130e27094b:0-mirm-incy-report-positive-rare-disease-data-as-fda-begins-nda-review-revised/", "source_name": "TradingView", "published_at": "2026-06-17T10:37:59", "published_display": "17 Jun 2026 10:37", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Incyte Corp (INCY) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Incyte Corp (INCY), highlighting its current earnings forecast score of 7.14 within the Pharmaceuticals industry and an average price target of $101.00 based on 28 analysts. The majority of analysts recommend a \"Buy\" for INCY, with e", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-incy/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T06:38:17", "published_display": "17 Jun 2026 06:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Incyte Corp (INCY) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Incyte Corp (INCY) has a robust financial health score of 9.25, ranking 7th out of 157 in the Pharmaceuticals industry. The company reported a significant year-over-year revenue increase of 20.87% to $1.27 billion, with net profit soaring by 91.73%. These figures indicate strong ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-incy/financial-health", "source_name": "TradingKey", "published_at": "2026-06-17T06:08:11", "published_display": "17 Jun 2026 06:08", "sentiment": "positive", "sentiment_pct": 77, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Incyte Corp (INCY) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "Incyte Corp (INCY) has a risk assessment score of 8.15, ranking 27 out of 157 in the Pharmaceuticals industry. The company's beta of 0.79 indicates it tends to underperform in up markets but has smaller declines in down markets. The U.S. Dollar Index's neutral state has a neutral", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-incy/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-17T06:08:06", "published_display": "17 Jun 2026 06:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Incyte Stock (US45337C1027): Clinical data and earnings outlook keep Nasdaq biotech in focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxQVHIyZGFHcWNSaFhybjZfb2J1VWp6WWlWSTVnT3NQZW1ZcFVIdEdJZDhTRFpHVENmamp5ZThNLVVxQ1JJdTBKbXBvYmlLbEgzUjB1RkdKOVJUaGpIUUNqcW5oOUFMREZPcjJPSDBYRnV3N2xyTTZtZFdBOEw3M0JBMUFNODhiMEZuMjFGaXNnT1BuX2ltbVk1dWNacTVQT2JJVEVsbXRCTkVrN2UxX0czT2RyRzQ0djVrUDRGU3d2RXBOdw?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-06-16T14:33:44+00:00", "published_display": "16 Jun 2026 14:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Conflicted on These Healthcare Names: Incyte (INCY), Intellia Therapeutics (NTLA) and Halozyme (HALO)", "summary": "Analysts have issued conflicting ratings for several healthcare stocks. Incyte (INCY) received a Hold rating from Wells Fargo, with a Moderate Buy consensus. Intellia Therapeutics (NTLA) was rated Buy by TD Cowen, holding a Moderate Buy consensus. Halozyme (HALO) also received a ", "url": "https://www.theglobeandmail.com/investing/markets/stocks/NTLA-Q/pressreleases/2489035/analysts-conflicted-on-these-healthcare-names-incyte-incy-intellia-therapeutics-ntla-and-halozyme-halo/", "source_name": "The Globe and Mail", "published_at": "2026-06-16T11:07:52", "published_display": "16 Jun 2026 11:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Offer Insights on Healthcare Companies: Incyte (INCY), Pfizer (PFE) and MBX Biosciences, Inc. (MBX)", "summary": "Barclays analysts have provided insights on several healthcare companies. Etzer Darout maintained a Buy rating for Incyte (INCY) with a $117.00 price target, while Emily Field issued a Sell rating for Pfizer (PFE) with a $25.00 price target. Eliana Merle maintained a Buy rating o", "url": "https://www.theglobeandmail.com/investing/markets/stocks/PFE/pressreleases/2486608/analysts-offer-insights-on-healthcare-companies-incyte-incy-pfizer-pfe-and-mbx-biosciences-inc-mbx/", "source_name": "The Globe and Mail", "published_at": "2026-06-16T08:40:35", "published_display": "16 Jun 2026 08:40", "sentiment": "positive", "sentiment_pct": 63, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BMO reiterates Incyte stock Underperform on ET/MF trial data", "summary": "BMO Capital reiterated an Underperform rating on Incyte Corp. with a $75.00 price target following updates on its mCALR antibody candidate, '989. The firm noted decreased efficacy in larger patient groups for essential thrombocythemia and mild regression in myelofibrosis monother", "url": "https://www.investing.com/news/analyst-ratings/bmo-reiterates-incyte-stock-underperform-on-etmf-trial-data-93CH-4742640", "source_name": "Investing.com", "published_at": "2026-06-16T04:37:57", "published_display": "16 Jun 2026 04:37", "sentiment": "negative", "sentiment_pct": 36, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Behavioral Patterns of INCY and Institutional Flows", "summary": "The article analyzes Incyte Corporation (INCY) with a strong overweight bias based on AI-generated signals across all time horizons. It identifies a mid-channel oscillation pattern and presents an exceptional short setup with a 34.6:1 risk-reward ratio. The analysis further detai", "url": "https://news.stocktradersdaily.com/news_release/17/Behavioral_Patterns_of_INCY_and_Institutional_Flows_061626025001_1781592601.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-16T02:50:00", "published_display": "16 Jun 2026 02:50", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Incyte slides as investors digest updated INCA033989 (mutCALR) data and a cautious analyst take", "summary": "Incyte (INCY) shares dropped 6.0% after investors reviewed updated clinical trial data for INCA033989, a mutant CALR-targeted antibody. Despite the company highlighting rapid and durable responses in essential thrombocythemia (ET) and myelofibrosis (MF), the stock reacted to perc", "url": "https://www.quiverquant.com/news/Incyte+slides+as+investors+digest+updated+INCA033989+%28mutCALR%29+data+and+a+cautious+analyst+take", "source_name": "Quiver Quantitative", "published_at": "2026-06-15T21:20:55", "published_display": "15 Jun 2026 21:20", "sentiment": "negative", "sentiment_pct": 38, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Incyte Corp. stock underperforms Monday when compared to competitors", "summary": "Incyte Corp. (INCY) shares decreased by 6.04% to $101.98 on Monday, despite a generally positive trading session where the S&P 500 Index and Dow Jones Industrial Average both saw gains. This fall ended a four-day winning streak for the company's stock.", "url": "https://www.marketwatch.com/data-news/incyte-corp-stock-underperforms-monday-when-compared-to-competitors-30e24eda-2ba4092076ab", "source_name": "MarketWatch", "published_at": "2026-06-15T20:30:00", "published_display": "15 Jun 2026 20:30", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Incyte Is Dropping 5.6%: HC Wainwright & Co. Maintains Buy", "summary": "Incyte Corporation's shares plunged 5.6% despite HC Wainwright & Co. maintaining a Buy rating and increasing its price target from $135 to $140. The market's reaction, with heavy trading volume, suggests investors are focusing on broader sector weakness, potential FDA regulatory ", "url": "https://news.alphastreet.com/why-incyte-is-dropping-5-6-hc-wainwright-co-maintains-buy/", "source_name": "AlphaStreet", "published_at": "2026-06-15T19:44:53", "published_display": "15 Jun 2026 19:44", "sentiment": "negative", "sentiment_pct": 37, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Incyte Corporation (INCY) Stock Analysis: A Biotech Innovator with a Robust Revenue Growth and Promising Pipeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8wFBVV95cUxNdG0yZ0pxNS04T3F1bzlfdldIX29oUzlFWHFpNm9PWVlmalVSRjBNWS1YTHNWZlNQVlRCQ1pHWjlyS3VVbHlQclZQSm9wc1pqTTdfY09NZ0N5c0tZSmZILUY1MnR3Slphel83aGFpRXAxS0R0Wk9LVmRROVdlZGxJdXEtdG9pWUZTQXNHMjQ0clVtS1doM1p0QVBFRHRrN2xXZEF5aUhQUEFjUkJGUVJlVTZzMVRqcUZvTDQwMkptbEFxTUw3LU4wVk5maE9lc0M5X2RZdzJBdzlLVzhCRENnM0pBNkNVNTl5dl9DSDJLdGhvYkk?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-06-15T09:13:37+00:00", "published_display": "15 Jun 2026 09:13", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Incyte antibody speeds platelet normalization in MF and ET trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxONTJaWldyWHNmbTg3c2lwcnItdk9mLVFLcUwyTFB5MC1LWGxJZFZfNXdEaFpGQ1FTdDg3allzODRyaENNZXdaTE50S3RCQWJXYzA1SE8xNVMxejhVMHJLU2RvWWo4cEQ5eHg0Z2dNRjAzZ3BLaW5mdjNzSmgyWUFJeGhiV1V2bjNMWENBRUpaTnZFOGEweS1LMzlGUzVXN2Rzd0ZsY0JYeHNCWE9sR0lkTzg4ZlJVN3VLOV9J?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-13T15:15:00+00:00", "published_display": "13 Jun 2026 15:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Incyte Stock (US45337C1027): Ownership shifts and pipeline focus keep shares in view", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxPQ0EtclJTazlVTzA2NEJ2RzV6LTRicTR1OEtCMlBvaUlNbVp4bEtPN1pGS185d2s1TlB2bk1HMGtKX0RBYW1CR0w2QmM5cU0weEdJeDg4YWV3S3JqbWVuV2hxQ2ZSLVRESlZPeDBoT0QxUWFIWEhBTWE4Z185ci1DV3JrS1otVTBKeXVtT2lUbjFqbGx1cVNBZ3F2LXY1c19lVVFCUmVFay1WVGtqTE1VbExvR1d5QjZkbDJXRHo1ODZLd3c?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-06-13T14:50:29+00:00", "published_display": "13 Jun 2026 14:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Incyte Stock (US45337C1027): Quarterly trends and sector context for US investors", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxOckxjX2hsMWNwc0haMFFTUDYzSjcyVHFVNHp1NFg4QXZWYW82Y3p4cGZpdERicTRUVVowemFSSFBZa2pQa0gtTWUyVTlmLWpLcmV4SXBkTlB3QzEzdzVzdkZkcml5aXkyT0dXblRLYUh2VkNlalpEbGFHU2Nfb2xDY0t4UEMtX214TUFvazBZamlJYURLc1g3QXhXOEdVRnVSM1hKTU5FRE0zbVJTTGhBNk9QUFZaRFJGdVN4SDFYc2t0MGtIdWc?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-06-12T08:05:21+00:00", "published_display": "12 Jun 2026 08:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Incyte a Better Buy Than Regeneron Pharmaceuticals?", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxQeEJUcW9pQ2IybVJvanh6TFNjeFFQbktWeUYxM2RiYWxtRzJ6V01tRHh5VllXVjcxVzhLUWpRYU9jMThUUjJrX09JdGdDN2ExTHNUUDRLTDdwenQzRVd4YlVwQzlqNmlId1BNbThDc0xNUmNGMlNCeU1CN194cW1mQlBYVlA3RnNJS2VPTy1TVnI2bnlhQjgtSHRGeHhFR2lxT2lzbEwwX0swM1hpVTY3Q2kyX04?oc=5", "source_name": "Trefis", "published_at": "2026-06-11T06:45:47+00:00", "published_display": "11 Jun 2026 06:45", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Incyte (INCY) Stock Is Up Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxQQ05OclRmVmRWM3NORGJHMzZ3RDNWNDI2cnM2WXZUSnJTdzZoRl92WjY0cDU5SFJjQjgtTWw4b01UZnNBWTF5alRobEJjVHd2MThkS0hBcWpZbTdfa2F1SGRMWlI0emVVUVRlMUNEaFM4cWpRVEdaYVBrUkVyUC1oam1RQlFac3F5QmZ4UUZ2OTkyVGhxS2EwRVFMMA?oc=5", "source_name": "StockStory", "published_at": "2026-06-10T16:15:00+00:00", "published_display": "10 Jun 2026 16:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Incyte to Buy Vega Therapeutics in Hematology Deal Worth Up to $2B", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQUDduNFJOWlY1ZjNXa3p0SDIxT3QxWDJvMlE1TGxwZTNlUWlNamxkUnI5THNIeEI3dEcwSmctMEladzZfX0pLMDFBWWQ2d0FxaTZ6a28wUWE1VmZ2d0kzbDl4dWJGTHZCSjhIeHhQckdGbC14SnhxUm9CazlWOUtMQWlBRVlodzE3VVY3RjNmTGE4SER5bU9EX2w5X3ZrbHhWVXNpRjljeE5pVXFETXNNMENIU3R2eDRXREo4ZW5B?oc=5", "source_name": "TradingView", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Incyte Corp (NASDAQ:INCY) Screens as a Deep Value Opportunity with Strong Profitability", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxOWFVlcU50TUMxa1owUkdndWwyNDY2SW80V3lLc3c4bDRQN3lrQUw1TnFQNERTdzh0RXZkUmw1RzRESUpDTjJCZHZxVks1T0l3Z1lqWUdfcGM1X2c2Tk80d0t2blVXX3k4eDd5MW5sT2dJbUkzV1NjY1dJdS1PRjhrQ0FNTU9UMHV3OV9pS2p6R3VnNHdHeEw0TGNZN2xkTFkzcXNudVBMUnFyeTVCZE1QdTY2ay1KazE5UDRyWURKMkp0d2w1bWw4Vk44R2xMQXMzR3c?oc=5", "source_name": "ChartMill", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Incyte shares rise 6.2% amid renewed optimism around late-stage pipeline and recent partnership update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxOenVCZlpfeW9CNXJCUmhoeUM1YWRHaHlZdnNadUhBTUpNTl9ZUmlXdHo5VHhEWWhpeHdPTFV2UTl5TmJfalp6b1dvdGMzV3hNQXI5Wm1zQmlaWVNvdkJZY2ZUMmlUTXdjZWJtRkJCTjBtQTBkejA0U1ZBN2FEZElDWlVqcjNwYmh2UXloUjFPaVdNWTRZVE1WdTVlT3NnYkxjcWtqZy1ZR2U1Uk1SdmZwVC1XbHU4UXp0aEQ4c0FRdHNGYUpJNUdUS2hvWWhnT3pRNkVv?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Incyte Corporation (INCY) Stock Analysis: Exploring a Strong 11.6% Potential Upside for Investors", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxOMV9sNkNFNDBoeGZzREV1eTlKZWVGN04xV1JTMThMN2cyYmp1SDlHS0dUYkRxVjFVRHFiYzNmdExfNlhKT0VSRnRWR3dubWtEb3M0THpudHNjM3Q4TG5TbUVWcXhnSGd1WGNLVWU1WXJxeWY0Y18tbksxZnhvelFTOXktU0VJX1NJREE3a21KNW9MWVpjUHh5b0RlbXRXZ1k3VFZzRm1lVktydTc3YjU3OFJqbmotdHNidk5mT2lmTHdBSUxCZ3RYOVY5c3lqTm1sbVZidmIwRzJDTkkt?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Impressive Earnings May Not Tell The Whole Story For Incyte (NASDAQ:INCY)", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-10T07:00:00+00:00", "published_display": "10 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jakafi XR Approval Tests Incyte Valuation As Growth Outlook Softens", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Consider Incyte (INCY) After A 55% One Year Rally?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-02T07:00:00+00:00", "published_display": "02 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "One pill a day: FDA approves Incyte's Jakafi XR for 3 conditions", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNelJqN3I0SmRrRmFFdi1EazhfbmlPSGIzVnh6U1lXcmhZZmNyMTVPOFgxb1ZEMXhPRVJubmZudDg1NFlyVVZ5a1FkMkloUHpiaVFzaVpFZW5HZmhHUUs0bk9sRTB3ckNRYUNjVjZvRDlZMmIwaE5ZdEZoY3Z4VGlGWi0tM2JtWnNTbUE1c2xweC02ZS1XQm5LYWd1SXZCWEliMEdEd012MTU1NmpsMGgzTVd4dWh3bm0wTXdXRw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Incyte (INCY) Margin Reset To 26.7% Tests Bullish Profit Durability Narratives", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxNVGxPS1U4Z2pBcy1KOG8yZzRaVUk0SHdxR0ltQ1Fkc2JqbTQzcW1rdUpZd0t1bkhsXzdPVWt4ZEFleGxPZ01ROGpJdm1LZ1AxWGZYRlZhbVNVaXkzbVQ5MS13Vk9BcWt1bDNPZHVlZVVRQUowTUo1WkJHdzF6bVkzMDZ1bVBRMnJkbDNiUXdEaHpQN2kxOG0wU1pEMDZiaUN4UmIxOGt4SjRUcGZKbEZUalBEN1RRMXhkTlFRTmtKemJWVGVqXzVtRlpFd3gyLV9YSk9SbTR4TdIB3AFBVV95cUxNQllVbVh3aGN4MlVRUGVJSGlZM1hlenMyaTZjUDloa0E1aTN3NkpvNmpIWEI0TFM1V25QLWdHUUFvUzU0TkRFcjZQcVVycmlNRjE5MFNwanRSejU1UWJIdlc5Mm11Y0JNbWpwRk1YdzdsZ2k4SzVoa2dGWU02RGQwcGE1R1ZRdTViQlB0WTdHaExxdGdTZDFKR29kLS1nN1gwYXJRc3dQdE5PQzdIT1F4MFNlTFZERmhOU1dubnBjUkEwaUV5VU1semNRQlJISXFvNDRqUE9vWTdFaGFr?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Incyte (NASDAQ:INCY) Beats Q1 Estimates and Unveils Robust Pipeline Catalysts", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOOW51ZjBlYUxHSjBUR3NsT2Y2MENXSXEtYkViTEwwMGd2Tm0wTTJpOW9vTTAyM2gxWVgtOWY1TjlvZFZZOXEwUklhY1lCZ3pBdGlHTTB3WHRaVVEzX1pMYjZnSUo3ekFnSlg5WHh2TW8wcU91ZTRMdXc1aHZtVHpOTmd3X2FESndBVnczcXM1QlNNc0dRUUZaajVIWFlGbS1pSW1nVnJXM095OVQ2TUZvd3BnZmpscm5tRVJaT0ZoU1JYbWpy?oc=5", "source_name": "ChartMill", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Incyte Gears Up to Report Q1 Earnings: What Can Investors Expect?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQR2h2RzNYQjhHeVU0Ul8tNTFsUllVRFRIMXUtNEthTU5fNF8xOXpEVVQ1LUVzY1BqYW9pMEFPaFhpYkUxWmcyNHJBZ0hub1ZDY2JmcVlQNVVFcjZka2pDOTY5ZUl5SGJGUnhEUjE0QzJCVnpWZHEwTUlwS25QRTRYWEtscHBXYXN3RkNzYnVXc013aDUxWVYya2NaNk9ZZlp4VHJhWEZUb2lVUXJCMW9tNVYyVjZyVGRrZ2tF?oc=5", "source_name": "TradingView", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Incyte (INCY) Stock Analysis | Incyte Corp Posts 8.5% EPS Miss Vs Consensus Views - Banking Earnings Report", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxOVFA1YUVTb0xLQWV6N0t4NTMzTC1qa2NzZllURDVwOFdQaXlTRFRTNlRGYXpNVlh6dVFhUXlJRW9wRFM0T1A5R3h2ZElzN2U4emJLSFJxNWtaSXlKRkpmQXZCWE9lQ2JyRk13ZmNwN25kMndKUHlRcDdvZUVmUm84X0dPYkxqbFBacXUyRFN6Q3BfcDVqZGt2Z2ZVWEg3UF9tOG5wcjJVdEpTbHd6aDBfd1Nn?oc=5", "source_name": "lwvtexas.org", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INCY Stock Analysis: Incyte Corp biotech stock rises 1.73 pct near 96 dollar mark", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxQcFgwSTl6UVBGY0hGQlhjYlZ6TjNuUGdBaVgyNDBkNV9BY0l2WkRPV2F0ODRUSTZXcWpQZTRGZUNDa0lGZTZKbGJaaEtfUDM3QkhFODNIc0MzekV5WXRxN1h2RDU1ejJDOEVIMlM2OHRXRlV5Ti1WR2xFRVQwNFB6LUhkdnNqT3BGdmlHTEdfeUEyS2RzVFZJb0t5dzR6RjM3c25MaTF5UldMXzJ5NTRTenJSSFJRbGlhVVBISG5VYzNhZkJIUzBkdkhR?oc=5", "source_name": "lwvtexas.org", "published_at": "2026-04-03T07:00:00+00:00", "published_display": "03 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNZXlTZHFHZVNxMktqZ0hVNURmdE1hUFpZZnlfdEVhMnVla2EyTWN6b2YwNkVhNllxUy1Bczl2a0ZUNk04Q3oyTEZSajdpMnFDVXJfRTlfLUdHQ05uS3FQZkhNWkJ0MDFENDJvRXR0ZGV1RDlYVmdWem96V29NeTg4YWRZWGNoMzM1emRoSExJbXdwZnJIWHpsYjVnT0FQVHZtUW5iVg?oc=5", "source_name": "Market source", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Incyte Shares Drop 8% Post-Earnings: Analysts Target $104 Amid 2026 Guidance Concerns", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPX2ota2xxdzhJU0JNOHhDcmtsZHZvS1k1NGZ3Y2FQajJDTUp1TEF6ckxPVXVmaEU5R0ptS1RJNnRFcTdGVGRLS3VJWjk4VllUaU9fQVRTU3Q0VWlMX1djVnBXX0hFY3FPMzNHanZTNXhpeVhIZ3BLR1ZNczl0dmVna1JHWTRYdTFqYjFmWjFiV0ZMOHRnY2M0bzJYaVQ4QVA3bU9IUkF2RkRLdlF5?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-11T08:00:00+00:00", "published_display": "11 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Incyte (INCY) Stock Is Nosediving", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxOZGpma0o0NWdYU0trcVNGN1lPWEVscThjSHloTERUSE5INnlpQXpYNktTZktaTUtVRXdZX25qZmFBTlZTcDYta3QxSUV0Y3ZfTzdEQkRKYkZ2cGJkU3Y1ZU5CX1M1Mm9DVzk5Z2FFOHJCZWVHY2N4Q1dhOVJlS3VKS1JxMnU?oc=5", "source_name": "Market source", "published_at": "2026-02-10T08:00:00+00:00", "published_display": "10 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INCY Stock Price and Chart \u2014 NASDAQ:INCY", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE52MEF3WHRDbDVpZHhrc3B4ejdpZWFNQXR0MElhRVFBdHNsRzZnVHB1WEtzaTdnbUp0S3N2UC1DZlRMRHZubHh5dUhVcFdwUm0zUFRNN1JNOTMzdy1L?oc=5", "source_name": "TradingView", "published_at": "2026-01-26T08:00:00+00:00", "published_display": "26 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Incyte (INCY) Stock Is Up, What You Need To Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNcEVObVhOODFvSlBHWS1DX0tlck1fOEstcmEwOUhIbnpLZ1puSlk0RWoxckdRbHY3Y0hoOUFqSHdHRFBqN1FqWFNYMllsdDJuRllVRkV6WWxaWGdoSEk0WVNiV0dDNHBLVXdYNW1maV9Wd0NyV21DOFVlb1ZNV1U5N19nMFpDTGJRMmhMZ1FyY25ETDRROGpvdno1SzdCSm1TaUljYTlrVDgteGZBVlE?oc=5", "source_name": "StockStory", "published_at": "2026-01-07T08:00:00+00:00", "published_display": "07 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Incyte and Winnie Harlow Join Forces to Share Her Personal Vitiligo Story and Spark Conversation and Understanding", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxNWGZFR2NTV2dLby04Q1pQcVNMd3owSDVIYndvOXl6VHlMUHpfTEJqUzZtUms3VHNBNmFIN3AwOUJxeXJwcVY2QWYxZGdlM2xWTENnQjVkZ1BLcHNJTm0xZjVXM2Y2VHpSb3ljcGdRRXNKcWFuWmhJdzdMMEdhVGpnZU5ZdkFnY2VKWkpLY1pkWk5qX0cybHQ3U2o5ZzhSMVZtb2NYMlE1bGdjNmNneVFjaDNlMFpyXzdaUGFPNlRQQ2RFZHlxaEVrVHpPclltNmRJNXdQWW5YSjk?oc=5", "source_name": "Investing News Network", "published_at": "2025-12-02T08:00:00+00:00", "published_display": "02 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Results: Incyte Corporation Beat Earnings Expectations And Analysts Now Have New Forecasts", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-10-31T07:00:00+00:00", "published_display": "31 Oct 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Incyte Corporation's (NASDAQ:INCY) Price Is Right But Growth Is Lacking After Shares Rocket 26%", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-08-14T07:00:00+00:00", "published_display": "14 Aug 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 101, "total_relevant": 58, "sentiment_summary": {"positive": 22, "negative": 7, "neutral": 29, "score": 56, "total": 58, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 75, "events": [{"event": "general", "label": "Market update", "weight": 13.55, "count": 24}, {"event": "earnings", "label": "Earnings", "weight": 9.07, "count": 18}, {"event": "analyst", "label": "Analyst action", "weight": 4.95, "count": 9}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.65, "count": 3}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 1.1, "count": 2}], "positive_events": 22, "negative_events": 7}, "market_context": {"has_market_context": true, "latest_close": 98.22, "latest_week": "2026-06-19", "one_week_move": -9.5, "four_week_move": 1.1, "twelve_week_move": 8.8, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.590216, "market_dynamics_buy_signal": false, "relative_strength": -12.215425, "fair_value_gap": 34.7, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 54.0376, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-9.5% over one week, +1.1% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 63, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "simplywall.st", "count": 9}, {"label": "AD HOC NEWS", "count": 6}, {"label": "Market source", "count": 6}, {"label": "TradingView", "count": 5}, {"label": "TradingKey", "count": 4}, {"label": "Investing.com", "count": 3}, {"label": "Stock Titan", "count": 3}, {"label": "ChartMill", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 52}, {"label": "Industry context", "count": 6}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 24}, {"label": "Earnings", "count": 18}, {"label": "Analyst action", "count": 9}, {"label": "Regulatory and legal", "count": 3}, {"label": "Deals and strategy", "count": 2}, {"label": "Guidance", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "56/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "75/100 classification confidence."}, {"label": "Company focus", "value": "52", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-9.5% over one week, +1.1% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Truist raises Incyte stock price target to $105 on VWD outlook"}], "updated_at": "2026-06-22T19:36:48.544975+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}